Here we will examine how an open model of precompetitive public–private research part- OPEN ACCESS nership is enabling efficient derisking and acceleration in the early stages of drug discovery, whilst also widening the range of communities participating in the process, such as patient Citation: Lee WH (2015) Open Access Target Validation Is a More Efficient Way to Accelerate Drug and disease foundations. Industry and academia are finally coming to terms with the fact that the prevalent models and incentives for innovation in early stage drug discovery are failing to promote progress quickly enough. There is a scarcity of novel treatments to address many unmet medical needs.
Open Access Target Validation Is a More Efficient Way to Accelerate Drug Discovery Open Access Target Validation Is a More Efficient Way to Accelerate Drug Discovery
